Dr. Hamburg, but in the second paragraph of your letter last December, you talked about, 'Importing non-FDA-approved drugs represents four potential risks.' No one is talking about importing non-FDA-approved drugs.
Dorgan clarifies that the discussion is about FDA-approved drugs, not non-approved ones.
Share
More from Byron Dorgan
We have now reached the tipping point that requires, in my judgment, action by Congress.
The efficiencies that would be driven from a non-profit corporation...would provide funding as well for excellent and stable and professional management.
I spoke on the floor of the Senate a number of times about general aviation and its importance to this country.
Other voices in this conversation
